In Haga et al.’s study, sorafenib therapy increased the expression and phosphorylation of c-Jun in human hepatoma cell lines with HBV integration, such as PLC/PRF/5 and HepG2.2.15. This evidence concerns the gene JUN and hepatocellular carcinoma.